<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00653302</url>
  </required_header>
  <id_info>
    <org_study_id>HOE901_4043</org_study_id>
    <nct_id>NCT00653302</nct_id>
  </id_info>
  <brief_title>Phenotype Evaluation in Insulin Naive Patients Using Lantus (Insulin Glargine)</brief_title>
  <acronym>GALATEE</acronym>
  <official_title>Assessment of the Phenotype of the Type 2 Diabetic Responders to the First Insulinisation Using Lantus (Insulin Glargine) Plus Glucophage (Metformin) Combination After Failure in OADs Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Primary objective:

        -  Efficacy assessment of the percentage of positive responders patients receiving Lantus
           plus glucophage association. Positive responders patients are defined by a final value
           of HbA1c&lt;7% and/or a final decrease of HbA1c&gt;15% compare to the basal value (HbA1c final
           - HbA1c basal).

      Secondary objectives:

        -  Determination of the predictive criterion of HbA1c final,

        -  Determination of the predictive criterion of weight variation,

        -  Description of the glycemic and therapeutic criteria in the both groups of responders
           (positive and negative responders),

        -  Assessment of the lipidic parameters according to the HbA1c and weight changes during
           the study (final value - basal value).

      Safety:

        -  Adverse Event (AE)/Serious Adverse Event (SAE) assessments
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2003</start_date>
  <completion_date type="Actual">October 2005</completion_date>
  <primary_completion_date type="Actual">September 2004</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>% of responders with HbA1c&lt;7% and/or a final decrease of HbA1c&gt;15% compare to the basal value (HbA1c final - HbA1c basal).</measure>
    <time_frame>During the study conduct</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determination of the predictive criterion of HbA1c final</measure>
    <time_frame>During the study conduct</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of the predictive criterion of weight variation</measure>
    <time_frame>During all the study conduct</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c and weight variations (final value - basal value)</measure>
    <time_frame>during the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AE/SAE evaluation</measure>
    <time_frame>from the informed consent signed up to the end of the study</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">280</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lantus once a day plus Glucophage 1000mg, twice a day per os</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lantus (insulin glargine) + Glucophage (Metformin)</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Known type 2 diabetes for at least 2 years

          -  No history of Ketoacidosis

          -  BMI&gt; 25 &amp; &lt;35 kg/m2

          -  Type 2 diabetes treated with oral bi or tritherapy for at least 6 months

               -  With insulin release stimulator: sulfonamide or glinide at maximal posology (as
                  defined in the SmPC),

               -  and metformin at minimal posology 1700mg/day (1320 mg of metformin),

          -  HbA1c &gt;= 7.5 and &lt;11% for 2 different dosages during the last year

        Exclusion Criteria:

          -  Type 1 diabetes

          -  Glucophage intolerability

          -  Pregnancy

          -  Breast feeding

          -  Partial pancreatectomy

          -  Hypersensitivity to insulin glargine excipient

          -  Renal failure with creatinin&gt;135 µmol/L for male and &gt;110 µmol/L for female patient

          -  Hepatitis with transaminases &gt;3ULN

          -  Pre-proliferative or proliferative retinopathy

          -  Acute cardiovascular accident within the last 6 months

          -  Previous treatment with insulin within the last 6 months before randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nathalie Billon</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi-aventis administrative office France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-aventis administrative office</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2008</study_first_submitted>
  <study_first_submitted_qc>April 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2008</study_first_posted>
  <last_update_submitted>December 2, 2008</last_update_submitted>
  <last_update_submitted_qc>December 2, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2008</last_update_posted>
  <responsible_party>
    <name_title>Nathalie Billon/Study Director</name_title>
    <organization>sanofi-aventis France</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

